rosacea
Conditions
Interventions
STBF-PDT group:0.5mg/ml STBF solution was evenly applied to the subject's facial treatment area, shielded from light for 0.5h, and illuminated by a LED instrument with a wavelength of 630nm and an ene
doxycycline group:Doxycycline, orally given once a day, 100mg, for 8 weeks
Sponsors
Shanghai Skin Disease Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Male or female, aged 18-65 years; (2) be diagnosis as rosacea based on the diagnostic criteria proposed by ROSCO; (3) All subjects were not suitable for medication for various reasons and voluntarily participated in and signed informed consent when informed of other alternatives, and agreed to have their lesions photographed.
Exclusion criteria
Exclusion criteria: (1) Patients who received photodynamic therapy or any other treatment which may affect study in 12 weeks; (2) Patients with other facial skin diseases that may affect the evaluation of efficacy; (3) Patients who have taken phototoxic or photosensitivity drugs in last 2 months; (4) Severely immunocompromised patients; (5) Patients who are prone to scar formation; (6) Patients who were allergic to chlorin, tetracyclines or with a history of photosensitivity; (7) Known or suspected liver damage or are receiving potentially hepatotoxic drugs; (8) patients with serious physical or mental diseases, and women in pregnancy or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Investigator Global Assessment of Rosacea Severity Score (IGA-RSS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinician's Erythema Assessment scale(CEA);Lesion regression rate; | — |
Countries
China
Contacts
Public ContactLinglin Zhang
Shanghai Skin Disease hospital
Outcome results
None listed